JP2005336127A - External preparation for skin - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an external preparation for the skin, which is excellent in usability and stability and enables transdermal absorption of a placental extract in an amount sufficient for exerting its whitening effect. <P>SOLUTION: The external preparation for the skin contains, based on the total mass of the preparation, 0.5-10.0 mass% phospholipid and 15-40 mass% placental extract. The external preparation for the skin is stable, shows good usability and enables excellent transdermal absorption of the placental extract to effectively exert its function against the skin. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a stable external preparation for skin containing a large amount of placenta extract and excellent in transdermal absorbability and usability.

  In order to prevent and improve blackening of skin due to ultraviolet rays, external preparations for skin containing various whitening agents have been provided. Among many well-known whitening agents, placenta extract has high safety and is one of the drugs attracting attention. However, the whitening effect of placenta extract is never high compared to other whitening agents. Accordingly, an attempt is made to add a large amount of placenta extract to the external preparation for skin, but even if it is added in a large amount, an amount of absorption into the skin corresponding to that amount cannot be obtained, and the whitening effect is still insufficient. In addition, the compatibility with other blending components is poor and stable blending is difficult, and discoloration and odor may occur over time. Furthermore, deterioration in usability due to a large amount of placenta extract is also observed.

  On the other hand, a liposome technology is known as a carrier for medicinal ingredients, and for example, a liposome technology containing 0.01 to 0.7% by weight of an unsaturated fatty acid has been disclosed (for example, see Patent Document 1). However, a technique for encapsulating a large amount of placenta extract in liposomes is not known, and its carrier function is completely unknown.

Japanese Patent Laid-Open No. 11-1423

  The present invention has been made in view of the above circumstances, and its object is to provide a skin external preparation with an amount of transdermal absorbability sufficient to exhibit the whitening effect of placenta extract and having excellent usability and stability. Is to provide.

  As a result of intensive studies to solve the above problems, the present inventors have found that the above problems can be solved by blending a large amount of placenta extract together with a specific amount of phospholipid into a skin external preparation. The invention has been completed.

  That is, the present invention contains a skin external preparation characterized by containing 0.5 to 10.0% by mass of phospholipid in the total amount of the external preparation for skin and 15 to 40% by mass of placenta extract in the total amount of the external preparation for skin. It is.

  In the present invention, in particular, 0.5 to 10.0% by mass of phospholipid is constituted in the total amount of the external preparation for skin, in which at least 15 to 40% by mass of the placenta extract is included in the total amount of external preparation for skin. By including the liposome as a component, the excellent effect according to the present invention is exhibited, which is a particularly preferable embodiment.

  The content of the placenta extract is preferably 1.5 to 50 times the mass of the phospholipid.

  The phospholipid is preferably a hydrogenated phospholipid.

  In the present invention, a methacryloyloxyethyl phosphorylcholine polymer can be further contained. The methacryloyloxyethyl phosphorylcholine polymer is preferably a copolymer of 2-methacryloyloxyethyl phosphorylcholine and a hydrophobic monomer.

  Moreover, in this invention, surfactant can also be contained.

  According to the present invention, a large amount of placenta extract is encapsulated in a liposome formed with a specific amount of phospholipid, in particular, a specific amount of phospholipid as a constituent component, and blended in an external preparation for skin. The skin absorbability is improved, the whitening effect based on the placenta extract is sufficiently exhibited, and a skin external preparation that is stable and excellent in usability can be obtained.

  Hereinafter, the best mode for carrying out the present invention will be described in detail.

  The placenta extract used in the present invention is an extract obtained from a mammalian placenta. Placenta extract is widely used in cosmetics, and is listed as a water-soluble placenta extract in the permission standard II for cosmetic varieties (supervised by the Ministry of Health and Welfare Pharmaceutical Affairs Bureau, Examination Division 2). The water-soluble placenta extract is a hormone-free extract obtained by removing blood from a healthy cow or pig placenta and then aseptically extracting with purified water and sterilizing to remove oil-soluble components. In this invention, what is generally marketed as a water-soluble placenta extract and is used as a cosmetic raw material can be used.

  The content of the placenta extract is 15 to 40% by mass in the total amount of the external preparation for skin as a pure component. If the content is less than 15% by mass, the effects of the present invention cannot be exhibited. Moreover, even if it contains exceeding 40 mass%, the further improvement of transdermal absorbability will not be seen, it will become difficult to formulate as a skin external preparation, it will not spread, and usability will also deteriorate. A more preferable content is 20 to 40% by mass in the total amount of the external preparation for skin. In addition, it is preferable that content of a placenta extract is 1.5-50 mass times with respect to the whole quantity of a phospholipid from the point of the stable mixing | blending of a placenta extract. More preferably, it is 1.5 to 35 mass times. In particular, 1.5-30 mass times is preferable.

  The phospholipid used in the present invention is not particularly limited as long as it is used for cosmetics, quasi drugs, pharmaceuticals and the like. In the present invention, phospholipid is a concept including natural phospholipids, phospholipid derivatives such as hydrogenated phospholipids, synthetic phospholipids, and the like. Examples of phospholipids include natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and sphingomyelin, hydrogenated phospholipids in which unsaturated carbon chains in natural phospholipids are saturated with hydrogen, and dioleylphosphatidylcholine. Synthetic phospholipids and the like. In the present invention, it is preferable to use hydrogenated phospholipid, and particularly hydrogenated soybean phospholipid. One phospholipid may be used alone, or two or more phospholipids may be appropriately selected and used.

  Content of the said phospholipid is 0.5-10.0 mass% in the skin external preparation whole quantity. If the content is less than 0.5% by mass, the effects of the present invention cannot be exhibited. In particular, sufficient transdermal absorbability of placenta extract cannot be obtained. Moreover, when it exceeds 10.0 mass%, usability will deteriorate. The preferable content of phospholipid is 1.0 to 5.0% by mass in the total amount of the external preparation for skin.

  In the external preparation for skin of the present invention, the placenta extract and the phospholipid are preferably contained in the external preparation for skin by encapsulating at least the placenta extract in a liposome containing phospholipid as a constituent component. The transdermal absorbability of the placenta extract is remarkably improved by converting the placenta extract into a liposome.

  The liposome encapsulating the placenta extract can be prepared by a known method without particular limitation. For example, phospholipids and placenta extract are dissolved or dispersed in water with other active ingredients such as polyhydric alcohols if necessary. In the dispersion, it is preferable to increase the dispersion by, for example, heating (for example, 80 to 90 ° C.), high-speed stirring (for example, a stirring speed of 3000 rpm or more with a homomixer) and the like. Subsequently, this dispersion is finely dispersed using a high-pressure mixer (for example, a microfluidizer, an APV homogenizer, etc.) to form liposomes. Subsequently, this dispersion liquid is cooled to room temperature to obtain a liposome dispersion liquid.

  Further, in the production method exemplified above, liposomes can be prepared with components other than the placenta extract, and then mixed with the placenta extract and, if necessary, other inclusion components, and stirred. In this case, the mixing and stirring of the liposome and the placenta extract is preferably high-speed stirring. In addition, as the liposome mixed with the placenta extract, it is also possible to use a liposome in which a sufficient amount of the placenta extract is not encapsulated. In preparing liposomes endosted with placenta extract by this method, it is possible to use liposomes that are not endostained with a commercially available placenta extract. Endosomal liposomes can be obtained efficiently.

  Examples of the liposomes that are commercially available include NIKKOL Aquasome BH, LA (manufactured by Nikko Chemicals) and the like. In the present invention, these commercially available products may be used as they are, but it is also an efficient method to convert them into specifications that are easy to use in preparing the external preparation for skin of the present invention, such as increasing the liposome concentration.

  In order to contain the liposomes containing the placenta extract in the skin preparation for external use, the liposomes in which the placenta extract is not contained, or a sufficient amount of the placenta extract is not contained, and the placenta extract are used for the skin preparation. It may be blended as one component of the formulation to form liposomes with endoscopy of placenta extract at a high concentration when preparing a skin external preparation.

  Liposomes are generally present as aqueous dispersions and are optionally diluted in water. In the skin external preparation, it is optionally diluted with water in the skin external preparation. The liposome in the present invention is a concept including an optionally diluted liposome aqueous dispersion present in the skin external preparation.

  A methacryloyloxyethyl phosphorylcholine-based polymer can be further added to the external preparation for skin of the present invention. By incorporating a methacryloyloxyethyl phosphorylcholine polymer, the transdermal absorbability of placenta extract is improved. Moreover, the methacryloyloxyethyl phosphorylcholine polymer can improve the stability of the liposome when the placenta extract is encapsulated in the liposome in the external preparation for skin, and can exhibit the excellent effect of the present invention. The methacryloyloxyethyl phosphorylcholine polymer can be mixed with phospholipids, placenta extract and the like at the time of liposome preparation, and used as a component of the liposome. In the present invention, it is preferable that the liposome containing such a methacryloyloxyethyl phosphorylcholine polymer as a constituent component is such that a work-in-progress is prepared in advance before preparing a skin external preparation.

  Examples of the methacryloyloxyethyl phosphorylcholine polymer include 2-methacryloyloxyethyl phosphorylcholine (hereinafter referred to as MPC) polymer (hereinafter referred to as MPC homopolymer), a copolymer of MPC and a hydrophobic monomer (hereinafter referred to as MPC). And the like, and these are preferably used.

  The hydrophobic monomer is not particularly limited as long as it can form a copolymer with MPC, but alkyl methacrylate or alkyl acrylate which is an alkyl ester of methacrylic acid or acrylic acid is preferable. More preferred is alkyl methacrylate. Examples of other hydrophobic monomers include styrene. The alkyl ester of methacrylic acid or acrylic acid preferably used can be polymerized with MPC by using both in combination, and is a preferred method of use. Also, a copolymer of MPC and alkyl methacrylate and a copolymer of MPC and alkyl acrylate may be mixed and blended into a makeup cosmetic. However, the copolymer of MPC, alkyl methacrylate and alkyl acrylate It is preferable to use coalescence. In the present invention, the alkyl of the alkyl ester of methacrylic acid or acrylic acid is preferably an alkyl having 1 to 8 carbon atoms. More preferably, it is C2-C6 alkyl. Specific examples of the hydrophobic monomer used in the present invention include, for example, methyl methacrylate, ethyl methacrylate, n-butyl methacrylate, 2-ethylhexyl methacrylate, methyl acrylate, ethyl acrylate, n-butyl acrylate, 2-ethylhexyl acrylate, styrene, and the like. Is mentioned. Of these hydrophobic monomers, n-butyl methacrylate is particularly preferable. One or two or more hydrophobic monomers are arbitrarily selected and used.

  The MPC homopolymer and MPC copolymer preferably used are both known substances, and can be obtained by reacting MPC or MPC with a hydrophobic monomer in the presence of a polymerization initiator according to a conventional method.

  One or two or more methacryloyloxyethyl phosphorylcholine polymers are used. In the present invention, it is particularly preferable to use an MPC copolymer. By using the MPC copolymer, the effect of the present invention can be remarkably exhibited.

  The molecular weight of the methacryloyloxyethyl phosphorylcholine polymer is preferably 100,000 to 1,000,000, more preferably 300,000 to 1,000 in terms of number average molecular weight in that the effect of the present invention is effectively exhibited. , 000. The constituent ratio (molar ratio) between the MPC unit and the hydrophobic monomer unit in the MPC copolymer is preferably in the range of 60:40 to 90:10. One or more methacryloyloxyethyl phosphorylcholine polymers are arbitrarily selected and blended.

  As the methacryloyloxyethyl phosphorylcholine polymer used in the present invention, a commercially available product can be used. Examples of commercially available products include Lipidure-HM, -HM-500, -PMB, and- PMB (ph10) (above, Nippon Oil & Fats Co., Ltd.) etc. are mentioned.

  As for content in the case of mix | blending a methacryloyloxyethyl phosphorylcholine type polymer, 0.1-10.0 mass% is preferable in the skin external preparation whole quantity.

  The skin external preparation of the present invention does not particularly require the addition of a surfactant, but does not hinder the addition of the surfactant. As the surfactant to be blended, a nonionic surfactant is preferable. When the placenta extract is encapsulated in the liposome by blending a nonionic surfactant, the stability of the liposome is improved and the excellent effects of the present invention are exhibited.

  The nonionic surfactant can be mixed with a phospholipid, a placenta extract, etc. during the preparation of the liposome, for example, and can be used as one component of the liposome. In the present invention, it is preferable that the liposome having such a nonionic surfactant as a constituent component is prepared in advance as a work-in-process before preparing a skin external preparation.

  Examples of nonionic surfactants include sorbitan fatty acid esters (such as sorbitan monostearate and sorbitan sesquioleate), glycerin fatty acids (such as glyceryl monostearate), and propylene glycol fatty acid esters (such as propylene glycol monostearate). ), Hydrogenated castor oil derivative, glycerin alkyl ether, polyoxyethylene (hereinafter referred to as POE) sorbitan fatty acid esters (POE sorbitan monooleate, POE sorbitan monostearate, etc.), POE sorbite fatty acid esters (POE sorbite monolaur) Rate), POE glycerin fatty acid esters (POE glycerin monoisostearate, etc.), polyethylene glycol (hereinafter referred to as PEG) fatty acid esters (PEG monoolee) , PEG distearate, etc.), POE alkyl ethers (POE2-octyldodecyl ether, etc.), POE alkylphenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE / polyoxypropylene (hereinafter referred to as POP) alkyl. Examples include ethers (POE / POP2-decyltetradecyl ether), tetronics, POE castor oil / hardened castor oil derivatives (POE castor oil, POE hardened castor oil, etc.), sucrose fatty acid esters, alkyl glucosides, and the like. it can. One or more nonionic surfactants are arbitrarily selected and blended.

  The content when the surfactant is blended is not particularly limited, but the surfactant content when used as a liposome constituent as a liposome stabilizer is 5 to 80 with respect to the phospholipid in the liposome. It is preferable to contain by mass. In this range, sufficient effects of the present invention can be obtained. The surfactant can be used by mixing with the methacryloyloxyethyl phosphorylcholine polymer.

  In the external preparation for skin of the present invention, in addition to the above components, other components that are usually used in external preparations for skin such as cosmetics, quasi-drugs, and pharmaceuticals can be appropriately blended within a range not impairing the effects of the present invention. it can. The optional compounding component is a description in which a substance contained in the component may correspond to a plurality of components, and also includes a description partially overlapping with the above, for example, oil, humectant, polyhydric alcohol, Thickener, water-soluble polymer, film-forming agent, water-insoluble polymer, oil gelling agent, polymer emulsion, powder, pigment, dye, lake, lower alcohol, saccharide, UV absorber, amino acids, vitamins , Whitening agent, skin activator, blood circulation promoter, antiseborrheic agent, anti-inflammatory agent (anti-inflammatory agent), plant extract, organic acid, organic amine, sequestering agent, pH adjuster, antioxidant , Antibacterial agents (preservative antiseptics), astringents, refreshing agents, fragrances, water and the like.

  Of the optional ingredients, specific examples of the oil include oils such as hydrogenated oil, owl, cacao butter, hydrogenated castor oil, olive oil, castor oil, macadamia nut oil, evening primrose oil; beeswax, lanolin, gay wax, Candelilla wax, carnauba wax, ibota wax, jojoba wax, jojoba oil, liquid lanolin and other waxes; solid paraffin, ceresin, microcrystalline wax, polyethylene wax, liquid paraffin, squalane, polybutene, volatile hydrocarbons and other hydrocarbon oils; Cetyl acid, isopropyl myristate, isopropyl palmitate, cetyl 2-ethylhexanoate, octyldodecyl myristate, octyl stearate, octyl palmitate, diisopropyl adipate, di-2-ethylhexyl sebacate, dica Neopentyl glycol phosphate, glyceryl trimyristate, glyceryl tri-2-ethylhexanoate, glyceryl trioctanoate, glyceryl triisostearate, diglyceryl diisostearate, diglyceryl triisostearate, pentaerythritol tetra-2-ethylhexanoate, Ester oils such as pentaerythritol dioctanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, diisostearyl malate; stearic acid, palmitic acid, myristic acid, 12-hydroxystearic acid, behe Higher fatty acids such as acid, isostearic acid and oleic acid; cetyl alcohol, stearyl alcohol, cetostearyl alcohol, behenyl alcohol, isostearyl alcohol Higher alcohols such as oleyl alcohol and octyldodecanol, chain polysiloxanes such as dimethylpolysiloxane, methylphenylpolysiloxane and diphenylpolysiloxane, cyclic such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane Examples thereof include modified polysiloxanes such as silicone, amino-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane. One or more oil components can be arbitrarily selected and blended.

  Among the optional blending components, specific examples of the polyhydric alcohol include, for example, glycerin, 1,3-butylene glycol (1,3-BG), 1,2-pentanediol, erythritol, sorbitol, xylitol, multi Tall, propylene glycol, dipropylene glycol, diglycerin and the like. One or more polyhydric alcohols are arbitrarily selected and blended.

  Specific examples of the humectant among the optional ingredients include, for example, amino acids, lactate (sodium, etc.), sodium pyrrolidonecarboxylate (PCA soda), urea and the like. One or more moisturizers are arbitrarily selected and blended.

  Among the optional components, specific examples of the water-soluble polymer include, for example, guar gum, quince seed, carrageenan, galactan, gum arabic, pectin, mannan, starch, pullulan, xanthan gum, curdlan, methylcellulose, hydroxyethylcellulose. Carboxymethyl cellulose, methyl hydroxypropyl cellulose, chondroitin sulfate, dermatan sulfate, glycogen, heparan sulfate, hyaluronic acid, sodium hyaluronate, tragacanth gum, keratan sulfate, chondroitin, mucoitin sulfate, hydroxyethyl guar gum, carboxymethyl guar gum, dextran, kerato sulfate, Locust bean gum, succinoglucan, caronic acid, chitin, chitosan, carboxymethyl chitin, agar, polyvinyl alcohol Lumpur, polyvinyl pyrrolidone, carboxyvinyl polymer, sodium polyacrylate, PEG, and the like. One or more water-soluble polymers can be arbitrarily selected and blended.

  The skin external preparation of the present invention can be prepared according to a conventional method by blending the above components. The dosage form of the external preparation for skin of the present invention is not particularly limited, but is preferably a gel type.

  Hereinafter, the present invention will be specifically described with reference to examples. A compounding quantity is the mass%. Prior to the description of the examples, the effect test method used in the present invention will be described.

1. Transdermal absorbability (1) Test method Pig skin coated with a sample added with fluorescent substance 4MUS (4-Methylumbelliferyl sulfate potassium salt) is placed in a Franz diffusion cell and left at 32 ° C for 24 hours. The 4MUS contained was decomposed with Sulfatase (Type IV from Limpets) and then quantified by fluorescence detection to measure the amount of absorption of the fluorescent substance.

(2) Evaluation From the absorbed amount and the ratio of the absorbed amount to the deep part of the skin with respect to the absorbed amount, the evaluation was performed based on the following criteria.
(Evaluation criteria)

(Absorption)
A: The detection rate of 4MUS with respect to the coating amount is 25% or more.
○: The detection rate of 4MUS with respect to the coating amount is 20% or more and less than 25%.
X: The detection rate of 4MUS with respect to the coating amount is less than 20%.

(Amount absorbed to the deep part)
A: 90% or more of the total absorbed amount.
○: 70% or more and less than 90% of the total absorption.
X: Less than 70% of the total absorption.

2. Stability Samples were stored in thermostats at 50 ° C., 37 ° C., 25 ° C., and 0 ° C., respectively, and appearance changes after one month were evaluated according to the following evaluation criteria.
(Evaluation criteria)
○: The system is stable without any system separation, discoloration, odor, etc. under any condition.
X: Under any condition, any of the system separation phenomenon, discoloration, odor change, etc. is seen and unstable.

3. Usability and Usability Each test product is used on a panel of 20 women, and the usability and usability of freshness, stickiness, skin transparency, etc. are judged and used according to the following criteria. Evaluated.

(Evaluation criteria)
A: More than 16 people judged to be excellent in usability and usability.
○: 11 to 15 people judged to have excellent usability and usability.
Δ: 6 to 10 people judged to have excellent usability and usability.
X: 5 or less people judged that usability and usability were excellent.

  Next, production examples of liposomes will be given. Liposomes were produced using the components listed in Table 1 by the following method. In Table 1, the ratio of each component used is shown in mass% (total blending amount 100 mass%).

(Production method)
(1) All the ingredients were weighed and dispersed while stirring.
(2) Thereafter, the mixture was heated to 80 to 90 ° C. and stirred at high speed with a homomixer to enhance dispersion.
(3) Next, the dispersion liquid of the above item (2) was finely dispersed using a high-pressure mixer (microfluidizer) to form liposomes.
(4) Next, this dispersion was cooled to room temperature to obtain a liposome dispersion.

In Table 1,
(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Examples 1 to 3, Comparative Examples 1 to 4]
A skin external preparation (gel cream) having the ingredients and blending amounts shown in Table 2 (blending amount 100% by mass in total) was prepared by the following method.

(Preparation method)
(Examples 1 and 2, Comparative Examples 1 and 3-4)
A. (2), (3) and (4) were mixed with (1) and stirred at a high speed at 50 to 60 ° C., and (1) was included in (2), (3) and (4).
B. (13) was added and dispersed in (13), and (12) was added and neutralized to form a gel.
C. A gel was added with (6), (7), (8) and (11), and A was added and stirred to prepare a skin external preparation (gel cream).

(Example 3, Comparative Example 2)
A. (13) was added and dispersed in (13), and (12) was added and neutralized to form a gel.
B. To this gel added with (5), (6), (7), (8), (9), (11), (1) is added and stirred to obtain a skin external preparation (gel cream). Prepared.

  An effect test was conducted on the external preparations for skin (gel cream) of Examples 1 to 3 and Comparative Examples 1 to 4, and the evaluation results are shown in Table 3.

  As can be seen from Table 3, the external preparations for skin of Examples 1, 2 and 3 (gels) containing a large amount of water-soluble placenta extract (30% by mass) together with 1.2% by mass of hydrogenated soybean phospholipid in the external preparation for skin. Cream) had an excellent effect. In particular, the skin external preparation (gel cream) of Example 2 blended with the MPC copolymer was further improved in percutaneous absorption and stability.

  On the other hand, the skin external preparation of Comparative Examples 1 and 2 in which a large amount of water-soluble placenta extract (30% by weight) is blended with 0.15% by mass and 15.0% by mass of hydrogenated soybean phospholipid in the external preparation for skin. (Gel cream) and the skin external preparation (gel cream) of Comparative Examples 3 and 4 in which the blending amount of the placenta extract is 10% by mass and 50% by mass in the external preparation for skin cannot exhibit the effects of the present invention. It was a thing.

  Examples of the external preparation for skin according to the present invention will be described below. In addition, manufacture was performed according to the method of Examples 1-3. Moreover, when the said effect test was done also about these, the outstanding result was obtained in all.

[Example 4] Gel cream component content (mass%)
Liposome A 30.0
Water-soluble placenta extract 30.0
Glycerin 7.0
1,3-BG 5.0
Dipropylene glycol 3.0
Phenoxyethanol 0.5
Sodium hyaluronate 5.0
PCA soda 0.1
Lactic acid soda 0.1
MPC copolymer (Note 1) 1.0
Carboxyvinyl polymer 0.8
Methylpolysiloxane 3.0
Natural vitamin E 0.1
Retinol palmitate 0.1
Pyridoxine dicaprate 0.1
Ascorbyl tetra-2-hexyldecanoate 0.2
Dipotassium glycyrrhizinate 0.1
Potassium hydroxide 0.3
Purified water residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 5] Gel cream component content (mass%)
Liposome F 35.0
Water-soluble placenta extract 20.0
Dipropylene glycol 5.0
1,3-BG 5.0
Phenoxyethanol 0.5
Hyaluronic acid 3.0
PCA soda 0.1
Lactic acid soda 0.2
MPC homopolymer (Note 1) 1.0
Carboxyvinyl polymer 0.3
Carboxymethylcellulose 0.3
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-HM-500 (manufactured by Nippon Oil & Fats Co., Ltd.) (The blending amount indicates the amount as MPC homopolymer solid content.)

[Example 6] Gel cream component content (mass%)
Liposome C 40.0
Water-soluble placenta extract 40.0
Glycerin 3.0
1,3-BG 8.0
Xylitol 2.0
Phenoxyethanol 0.5
Hyaluronic acid 5.0
PCA soda 0.1
Lactic acid soda 1.0
MPC copolymer (Note 1) 3.0
Carboxyvinyl polymer 0.5
Hydroxyethyl cellulose 0.5
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 7] Gel cream component content (mass%)
Liposome D 30.0
Water-soluble placenta extract 25.0
POE (60) hydrogenated castor oil 0.2
Glycerin 5.0
Sorbitol 2.0
Phenoxyethanol 0.5
Hyaluronic acid 0.5
PCA soda 5.0
Lactic acid soda 0.1
MPC copolymer (Note 1) 2.0
Carboxyvinyl polymer 1.0
Carrageenan 0.1
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 8] Gel cream component content (mass%)
Liposome E 40.0
Water-soluble placenta extract 30.0
Glycerin 3.0
1,3-BG 5.0
Phenoxyethanol 0.5
Hyaluronic acid 0.1
PCA soda 0.2
Lactic acid soda 0.2
Carboxyvinyl polymer 0.5
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

[Example 9] Gel cream component content (mass%)
Liposome H 30.0
Water-soluble placenta extract 22.5
Glycerin 5.0
Dipropylene glycol 10.0
Phenoxyethanol 0.5
Hyaluronic acid 3.0
PCA soda 2.0
Lactic acid soda 2.0
MPC copolymer (Note 1) 6.0
Carboxyvinyl polymer 0.8
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 10] Gel cream component content (mass%)
Liposomes (Note 1) 30.0
Water-soluble placenta extract 30.0
POE (60) hydrogenated castor oil 0.1
Glycerin 3.0
1,3-BG 7.0
Phenoxyethanol 0.5
Hyaluronic acid 4.0
PCA soda 2.0
Lactic acid soda 2.0
MPC copolymer (Note 2) 1.0
Carboxyvinyl polymer 0.7
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) NIKKOL Aquasome BH Conch (Nikko Chemicals)
component
Polyoxyethylene hydrogenated castor oil (60EO) 1.0% by mass
1,3-BG 6.0 mass%
Hydrogenated soybean phospholipid 4.0% by mass
1,2-pentadiol 4.5% by mass
Purified water 84.5% by mass
(Note 2) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 11] Gel cream component content (mass%)
Water-soluble placenta extract 30.0
Hydrogenated soybean phospholipid 1.0
Glycerin 3.0
Propylene glycol 5.0
1,3-BG 2.0
Phenoxyethanol 0.5
Hyaluronic acid 1.0
PCA soda 1.0
Lactic acid soda 1.0
MPC copolymer (Note 1) 3.0
Carboxyvinyl polymer 0.5
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 12] Gel cream component content (mass%)
Water-soluble placenta extract 30.0
Hydrogenated soybean phospholipid 4.0
Glycerin 5.0
1,3-BG 7.0
Phenoxyethanol 0.5
Hyaluronic acid 3.0
PCA soda 0.1
Lactic acid soda 1.0
MPC copolymer (Note 1) 1.0
Carboxyvinyl polymer 0.8
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

[Example 13] Gel cream component content (mass%)
Liposome F 25.0
Water-soluble placenta extract 30.0
Hydrogenated soybean phospholipid 2.0
Glycerin 5.0
1,3-BG 7.0
Phenoxyethanol 0.5
Hyaluronic acid 5.0
PCA soda 0.01
Lactic acid soda 0.01
MPC copolymer (Note 1) 1.0
Carboxyvinyl polymer 0.8
Vitamin E acetate 0.1
Methylpolysiloxane 3.0
Caustic potash 0.3
Dipotassium glycyrrhizinate 0.1
Antioxidant Appropriate amount Preservative Appropriate amount Fragrance Appropriate amount Purified water Residue
Total 100.0

(Note 1) Lipidure-PMB (manufactured by Nippon Oil & Fats Co., Ltd.) (The amount is shown as the amount of MPC copolymer solids.)

Claims (7)

  A skin external preparation comprising 0.5 to 10.0% by mass of a phospholipid in the total amount of the external preparation for skin and 15 to 40% by mass of placenta extract in the total amount of the external preparation for skin.   Skin containing at least 0.5 to 10.0% by mass of phospholipid as a constituent component in the total amount of external preparation for skin containing 15 to 40% by mass of placenta extract in the total amount of external preparation for skin Topical agent.   The skin external preparation according to claim 1 or 2, wherein the content of the placenta extract is 1.5 to 50 times by mass with respect to the phospholipid.   The external preparation for skin according to any one of claims 1 to 3, wherein the phospholipid is a hydrogenated phospholipid.   The skin external preparation according to any one of claims 1 to 4, further comprising a methacryloyloxyethyl phosphorylcholine polymer.   The external preparation for skin according to claim 5, wherein the methacryloyloxyethyl phosphorylcholine polymer is a copolymer of 2-methacryloyloxyethyl phosphorylcholine and a hydrophobic monomer.   Furthermore, surfactant is contained, The skin external preparation as described in any one of Claims 1 thru | or 6 characterized by the above-mentioned.